A panel of experts summarizes the current HR+ breast cancer treatment landscape and discusses recent data updates in the field, including those presented at the 2022 San Antonio Breast Cancer Symposium (SABCS).
EP. 4: Subcutaneous vs Intravenous Pertuzumab/Trastuzumab for Treatment of HER2+ Early Breast CancerJanuary 30th 2023
The panel shares the factors that influence whether they recommend a subcutaneous or intravenous formulation of pertuzumab/trastuzumab in addition to chemotherapy.
EP. 6: Expert Perspectives on Clinical Experience with Ado-Trastuzumab Emtansine (T-DM1)February 7th 2023
The panel explains their clinical experiences with using the antibody-drug conjugate (ADC) ado-trastuzumab emtansine (T-DM1) to treat HER2+ early breast cancer.
EP. 7: Clinical Data Updates on Adjuvant Pertuzumab/Trastuzumab for HER2+ Early Breast CancerFebruary 13th 2023
A review of recently reported data on the use of adjuvant pertuzumab/trastuzumab for the treatment of HER2+ early breast cancer, including data from the APHINITY and PHranceSCa trials.
EP. 8: Extended Adjuvant Neratinib Therapy for Patients with HER2+ Early Breast CancerFebruary 13th 2023
Joyce O’Shaughnessy, MD, starts a conversation on which patients with HER2+ early breast cancer are the best candidates for extended adjuvant neratinib therapy.
EP. 11: Second-Line Treatment of HER2+ mBC and Recent Data UpdatesFebruary 27th 2023
Maryam Lustberg, MD, MPH introduces the standard of care regimens for the second-line treatment of HER2+ metastatic breast cancer, followed by a discussion of recent data on the ADC trastuzumab deruxtecan (T-DXd).
EP. 12: Options for Third- and Further-Line Treatment of HER2+ mBCFebruary 27th 2023
Dr Debu Tripathy explains the treatment options for patients with HER2+ metastatic breast cancer in the third-line and later-line settings, including combination tucatinib/trastuzumab/capecitabine.
EP. 13: Use of MRI for Surveillance of Brain Metastases in Patients with HER2+ mBCMarch 6th 2023
The panel discusses the management of patients with HER2+ mBC with asymptomatic brain mets and shares their thoughts on the use of surveillance brain MRI in this setting.